| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 190 | 2019 |
| Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature 608 (7921), 199-208, 2022 | 125 | 2022 |
| BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression EW Warner, C Herberts, S Fu, SM Yip, A Wong, G Wang, E Ritch, ... Clinical Cancer Research, 2021 | 82 | 2021 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 80 | 2020 |
| Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 73 | 2020 |
| Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ... Clinical Cancer Research 27 (16), 4610-4623, 2021 | 69 | 2021 |
| Technical and biological constraints on ctDNA-based genotyping C Herberts, AW Wyatt Trends in Cancer 7 (11), 995-1009, 2021 | 60 | 2021 |
| Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ... The Journal of pathology 246 (2), 244-253, 2018 | 50 | 2018 |
| Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer V Genitsch, A Kollár, G Vandekerkhove, J Blarer, M Furrer, M Annala, ... Urologic Oncology: Seminars and Original Investigations 37 (11), 826-836, 2019 | 44 | 2019 |
| The 5-hydroxymethylcytosine landscape of prostate cancer M Sjöström, SG Zhao, S Levy, M Zhang, Y Ning, R Shrestha, A Lundberg, ... Cancer research 82 (21), 3888-3902, 2022 | 42 | 2022 |
| Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer NM Fonseca, C Maurice-Dror, C Herberts, W Tu, W Fan, AJ Murtha, ... Nature Communications 15 (1), 1828, 2024 | 29 | 2024 |
| Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer SH Tolmeijer, E Boerrigter, T Sumiyoshi, EM Kwan, SWS Ng, M Annala, ... Clinical Cancer Research 29 (15), 2835-2844, 2023 | 29 | 2023 |
| Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy JVW Bacon, DC Müller, E Ritch, M Annala, SG Dugas, C Herberts, ... European Urology Oncology 5 (6), 677-686, 2022 | 17 | 2022 |
| Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping EW Warner, K Van der Eecken, AJ Murtha, EM Kwan, C Herberts, J Sipola, ... Nature Cancer 5 (1), 114-130, 2024 | 15 | 2024 |
| Genetic and genomic testing for prostate cancer: beyond DNA repair C Herberts, AW Wyatt, PL Nguyen, HH Cheng American Society of Clinical Oncology Educational Book 43, e390384, 2023 | 15 | 2023 |
| Genomic features of lung-recurrent hormone-sensitive prostate cancer NM Fonseca, K Van der Eecken, C Herberts, S Verbeke, SWS Ng, ... JCO precision oncology 6, e2100543, 2022 | 9 | 2022 |
| Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). C Maurice-Dror, N Fonseca, C Herberts, W Fan, AW Wyatt, KN Chi Journal of Clinical Oncology 39 (15_suppl), 5049-5049, 2021 | 9 | 2021 |
| A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes EJ Ritch, C Herberts, EW Warner, SWS Ng, EM Kwan, JVW Bacon, ... NPJ Precision Oncology 7 (1), 27, 2023 | 7 | 2023 |
| Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC). C Maurice-Dror, N Fonseca, C Herberts, EM Kwan, C Kollmannsberger, ... Journal of Clinical Oncology 40 (16_suppl), 5055-5055, 2022 | 2 | 2022 |
| Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC) SYF Fu, A Murtha, C Herberts, S Yip, A Angeles, SJ Hotte, A Alshangiti, ... Annals of Oncology 30, v347, 2019 | 1 | 2019 |
Alexander WyattAssociate Professor, University of British ColumbiaVerified email at prostatecentre.com